A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation

Table 2 Clinical characteristics after 6 weeks of dapagliflozin treatment (mean ± SD)

	Placebo		Dapagliflozin		p value placebo vs. dapagliflozin
	Absolute value (change from baseline)	p value vs. baseline	Absolute value (change from baseline)	p value vs. baseline	p value placebo vs. dapagliflozin
HbA1c (%)^a	6.79 ± 0.8 (0.12 ± 0.5)	0.064	6.62 ± 0.7 (−0.05 ± 0.3)	0.224	<0.001
Glucose
Fasting (mg/dl)	135 ± 32 (+2.3 ± 18)	0.325	114 ± 19 (−18.3 ± 16)	<0.001	<0.001
Postprandial (mg/dl)^b	180 ± 67 (+1.2 ± 31)	0.766	154 ± 46 (−24.8 ± 40)	<0.001	<0.001
Insulin (mU/l)	12.9 ± 10.6 (+0.8 ± 5.5)	0.276	9.7 ± 5.4 (−2.4 ± 4.1)	<0.001	0.002
HOMA index	4.48 ± 4.7 (+0.46 ± 2.5)	0.157	2.77 ± 1.7 (−1.25 ± 1.8)	<0.001	0.001
BMI (kg/m²)	29.9 ± 4.2 (+0.0 ± 0.7)	0.846	29.5 ± 4.1 (−0.30 ± 0.7)	<0.001	<0.001
Office blood pressure
Systolic (mmHg)	129 ± 13 (−1 ± 10)	0.340	126 ± 12 (−4 ± 12)	0.015	0.102
Diastolic (mmHg)	79 ± 9 (0 ± 6)	0.984	78 ± 9 (−1 ± 6)	0.058	0.113
Heart rate (bpm)	67.8 ± 9.6 (−1.3 ± 6.2)	0.123	68.2 ± 10.6 (−0.8 ± 6.5)	0.332	0.659
24-h ambulatory blood pressure
Systolic (mmHg)	129 ± 11 (−1 ± 10)	0.682	126 ± 11 (−3 ± 10)	0.010	0.021
Diastolic (mmHg)	77 ± 7 (0 ± 6)	0.765	75 ± 8 (−2 ± 6)	0.024	0.027
Heart rate (bpm)	75.7 ± 9.5 (+1.4 ± 6.8)	0.172	74.1 ± 7.6 (−0.8 ± 6.0)	0.351	0.132
Lipids (mg/dl)
LDL-C	142 ± 31 (−1 ± 23)	0.688	144 ± 31 (+1 ± 21)	0.808	0.478
HDL-C	48.5 ± 11 (+0.3 ± 4.8)	0.607	48.5 ± 12 (+0.4 ± 4.4)	0.541	0.954
Total cholesterol	207 ± 37 (0 ± 30)	0.937	209 ± 38 (+2 ± 26)	0.584	0.657
Triglycerides	159 ± 100 (+10 ± 91)	0.394	146 ± 74 (−3 ± 63)	0.684	0.043

N = 59
BMI body mass index, HbA1c glycosylated haemoglobin, HOMA homeostatic model assessment, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol
^a 6.79% = 51 mmol/mol; 6.62% = 49 mmol/mol
^b A standardised breakfast was given

ISSN: 1475-2840